title: [The role of FDG-PET in staging of lymphoma and evaluation of therapeutic efficiency].
abstract: OBJECTIVE
  To evaluate the application of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) to the staging and detecting residual masses of lymphoma.
  
  
  METHODS
  The clinical data of 179 patients with lymphoma were analyzed retrospectively. The results of FDG-PET, computed tomography (CT) and bone marrow biopsy (BMB) were compared for detection of lymph node/extranodal lymphoid tissue and bone marrow infiltration. Therapeutic efficiency was assessed by International Workshop Criteria (IWC) and Revised Integrated International Workshop Criteria (IWC + PET).
  
  
  RESULTS
  In the detection of 286 disease focuses in 98 patients before chemotherapy, the sensitivities of FDG-PET and CT were 73% and 70% (P < 0.01) in detecting nodal focus,and 87% and 45% (P < 0.01) in detecting extranodal lymphoma respectively. In detection of 104 lesions in 81 patients after chemotherapy,the sensitivities of FDG-PET and CT were 81% and 55% respectively (P < 0.01), and the specificities were 68% and 33%, respectively (P < 0.01) in detecting residual masses. According to IWC criteria, 33 patients achieved complete response/unconfirmed complete response (CR/CRu) , and 8 (24%) relapsed. Patients with PET-positive residual masses had a relapse rate of 40%, whereas only 21% of those with no such masses relapsed. Based on IWC + PET criteria, 25 patients achieved CR, with a relapse rate of 20%. Both FDG-PET and BMB produced positive results in 133/179 (74%) patients. Twenty-two patients with positive FDG-PET results were not detected by BMB. The sensitivities and specificities of FDG-PET for BM infiltration were 52% and 83%, respectively.
  
  
  CONCLUSIONS
  FDG-PET is a high sensitive and specific technique in staging and detecting residual masses of lymphoma.
authors.affiliation: Department of Hematology, Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai 200080, China.
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Zhou
authors.forename: Chun
authors.initials: C
authors.lastname: Wang
authors.forename: Jin-Hua
authors.initials: JH
authors.lastname: Zhao
authors.forename: Shi-Ke
authors.initials: SK
authors.lastname: Yan
authors.forename: Yan-Rong
authors.initials: YR
authors.lastname: Gao
authors.forename: Qi
authors.initials: Q
authors.lastname: Cai
authors.forename: Jie-Ling
authors.initials: JL
authors.lastname: Jiang
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Wan
authors.forename: Juan
authors.initials: J
authors.lastname: Yang
authors.forename: Ju
authors.initials: J
authors.lastname: Wei
authors.forename: Min
authors.initials: M
authors.lastname: Zhao
authors.forename: Hai-Tao
authors.initials: HT
authors.lastname: Bai
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology; D008223:Lymphoma / Q000000981:diagnostic imaging* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D055815:Young Adult
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18